small molecule

IRESSA

GEFITINIB

Loss of exclusivityloss of exclusivity
CompanyASTRAZENECA UK LTD

Drug detail

Brand nameIRESSA
Active ingredientGEFITINIB
Strength250MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2003
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

IRESSA patent cliff — loss of exclusivity — | CliffBio